PMID- 32420065
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220414
IS  - 2218-6751 (Print)
IS  - 2226-4477 (Electronic)
IS  - 2218-6751 (Linking)
VI  - 9
IP  - 2
DP  - 2020 Apr
TI  - Novel ALK-specific mRNA in situ hybridization assay for non-small-cell lung 
      carcinoma.
PG  - 257-268
LID - 10.21037/tlcr.2020.03.04 [doi]
AB  - BACKGROUND: A recent technical advance in mRNA in situ hybridization (mRNA-ISH) 
      assays provides simultaneous signal amplification and background suppression with 
      a unique probe design that enables single-molecule visualization. We assessed the 
      utility of the mRNA-ISH assay as a diagnostic tool for detecting anaplastic 
      lymphoma receptor tyrosine kinase (ALK) mRNA in non-small-cell lung carcinoma 
      (NSCLC). We compared the mRNA-ISH assay with immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH). METHODS: The study included 279 
      surgically resected lung adenocarcinomas and 44 transbronchial-biopsied (TBB) 
      adenocarcinomas. mRNA-ISH was conducted using the RNAscope 2.0 system, which 
      includes pre-designed probes for detecting the tyrosine kinase domain encoded in 
      ALK mRNA. IHC was conducted on all 323 samples using ALK-specific antibodies. 
      mRNA-ISH was performed on 279 surgical samples and 6 TBB samples. Break-apart 
      FISH was used to examine samples that were mRNA-ISH-positive or IHC-positive. 
      RESULTS: ALK protein expression was detected in 11 of 279 specimens (3.9%). ALK 
      mRNA was also detected with mRNA-ISH in ALK-positive samples, and 9 of the 11 
      specimens (81%) were also positive for ALK using break-apart FISH. Using the IHC 
      results as a reference, the sensitivity and specificity of mRNA-ISH was 100%. In 
      the TBB cohort, ALK protein expression was observed in 3 of 44 specimens (6.8%), 
      in which ALK mRNA expression was also detected. CONCLUSIONS: The ALK mRNA-ISH 
      data were highly correlated with the IHC data, and ALK mRNA-ISH detected ALK mRNA 
      expression in every FISH-positive sample. We conclude that mRNA-ISH could serve 
      as an alternative or complementary method for diagnosing ALK rearrangements in 
      NSCLC.
CI  - 2020 Translational Lung Cancer Research. All rights reserved.
FAU - Hirai, Noriko
AU  - Hirai N
AD  - Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
FAU - Sasaki, Takaaki
AU  - Sasaki T
AD  - Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
FAU - Okumura, Shunsuke
AU  - Okumura S
AD  - Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
FAU - Sado, Masatoshi
AU  - Sado M
AD  - Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 
      Japan.
FAU - Akiyama, Naoko
AU  - Akiyama N
AD  - Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 
      Japan.
FAU - Kitada, Masahiro
AU  - Kitada M
AD  - Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
AD  - Breast Disease Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
FAU - Takei, Hidehiro
AU  - Takei H
AD  - Department of Pathology, Asahikawa Medical University, Asahikawa, Hokkaido, 
      Japan.
FAU - Ohsaki, Yoshinobu
AU  - Ohsaki Y
AD  - Respiratory Center, Asahikawa Medical University, Asahikawa, Hokkaido, Japan.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Transl Lung Cancer Res
JT  - Translational lung cancer research
JID - 101646875
PMC - PMC7225155
OTO - NOTNLM
OT  - Anaplastic lymphoma receptor tyrosine kinase (ALK)
OT  - fluorescence in situ hybridization (FISH)
OT  - immunohistochemistry (IHC)
OT  - lung adenocarcinoma
OT  - mRNA in situ hybridization (mRNA-ISH)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/tlcr.2020.03.04). The authors have 
      no conflicts of interest to declare.
EDAT- 2020/05/19 06:00
MHDA- 2020/05/19 06:01
PMCR- 2020/04/01
CRDT- 2020/05/19 06:00
PHST- 2020/05/19 06:00 [entrez]
PHST- 2020/05/19 06:00 [pubmed]
PHST- 2020/05/19 06:01 [medline]
PHST- 2020/04/01 00:00 [pmc-release]
AID - tlcr-09-02-257 [pii]
AID - 10.21037/tlcr.2020.03.04 [doi]
PST - ppublish
SO  - Transl Lung Cancer Res. 2020 Apr;9(2):257-268. doi: 10.21037/tlcr.2020.03.04.